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Abstract
BACKGROUND—Gaps in screening quality in community practice have been well documented. 
The authors examined recommended indicators of screening quality in the Centers for Disease 
Control and Prevention’s Colorectal Cancer Screening Demonstration Program (CRCSDP), which 
provided colorectal cancer screening and diagnostic services between 2005 and 2009 for 
asymptomatic, low-income, underinsured, or uninsured individuals at 5 sites around the United 
States.
METHODS—For each client screened in the CRCSDP, a standardized set of colorectal cancer 
clinical data elements was collected. Data regarding client age, screening history, risk level, 
screening test indication, results, and recommendation for the next test were analyzed. For 
colonoscopies, data were analyzed regarding whether the cecum was reached, bowel preparation 
was adequate, and identified lesions were completely removed.
RESULTS—Overall, 53% of the fecal occult blood tests (FOBTs) (2295 tests) distributed were 
completed and returned. At the 2 sites with adequate numbers of FOBTs, 77% and 97%, 
respectively, of clients with positive results received follow-up colonoscopies. Site-specific cecal 
intubation rates ranged from 90% to 98%. Adenoma detection rates were 32% for men and 21% 
for women. For approximately one-third of colonoscopies, the recommended interval to the next 
test was shorter than recommended by national guidelines. At some sites, endoscopists failed to 
report on the adequacy of bowel preparation and completeness of polyp removal.
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CONCLUSIONS—Cecal intubation rates and adenoma detection rates met recommended levels. 
The authors identified the need for improvements in the follow-up of positive FOBTs, 
documentation of important elements in colonoscopy reports, and recommendations for 
rescreening or surveillance intervals after colonoscopy. Monitoring quality indicators is important 
to improve screening quality.
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INTRODUCTION
Screening for colorectal cancer can decrease the incidence of and death from this disease 
and is recommended in clinical practice guidelines.1–6 To achieve the maximum benefit 
with minimal harm, screening must be implemented appropriately, with adequate attention 
to quality assurance. Problems with the implementation of colorectal cancer screening in 
clinical practice have been well documented for all of the recommended screening methods, 
including the 2 most commonly used options: fecal occult blood test (FOBT) and 
colonoscopy.7–12
The collection of specimens for FOBT in the clinician’s office at the time of digital rectal 
examination rather than by the patient at home is a common practice, even though the in-
office test has extremely low sensitivity and is not recommended for colorectal cancer 
screening.8–10 Achieving high return rates when patients are given home tests is most likely 
the greatest challenge to the successful implementation of an FOBT screening program. 
Although FOBT can only be effective as a screening test when positive results are followed 
by complete examination of the colon and removal of identified polyps or cancers, a lack of 
follow-up of positive FOBTs has been documented in numerous local studies and national 
surveys.8 Approximately one-third of individuals who reported having had a positive FOBT 
in the National Health Interview Surveys conducted in both 2000 and 2005 reported no 
follow-up to their positive tests.
Wide variations in the quality of performance and documentation of colonoscopy, the most 
commonly used colorectal cancer screening method, have been described and are a growing 
concern in the gastroenterology and public health communities.11,12 Numerous studies have 
found a wide range in the rates of adenoma detection among endoscopists. The adequacy of 
procedure reports has been shown to vary, with some endoscopists failing to report critical 
elements.13,14 Recommendations for rescreening or surveillance intervals until the next test 
are often not in compliance with national guidelines.15,16 To reduce the variation in test 
performance and improve outcomes, it has been recommended that every colonoscopy 
practice institute a continuous quality improvement process in which quality indicators are 
routinely monitored and deficient performance corrected.11
In this study, we examined data related to the quality of screening services with FOBT and 
colonoscopy from the 5 sites that participated in the Centers for Disease Control and 
Prevention (CDC)’s Colorectal Cancer Screening Demonstration Program (CRCSDP) 
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between 2005 and 2009. The quality indicators assessed included return rate and appropriate 
follow-up of FOBT, cecal intubation rates, adenoma detection rates, reporting adequacy and 
recommended rescreening and surveillance intervals for colonoscopy.
MATERIALS AND METHODS
The CDC-funded CRCSDP provided screening, diagnostic, and surveillance services for 
colorectal cancer for asymptomatic, low-income individuals who were underinsured or 
uninsured in Baltimore, Maryland (Baltimore City); St. Louis, Missouri (St. Louis); the state 
of Nebraska (Nebraska); King, Clallam, and Jefferson counties in Washington State (Greater 
Seattle); and Suffolk County in New York (Suffolk County, NY) between 2005 and 2009. A 
detailed description of the program is provided elsewhere.17,18
St. Louis, Nebraska, and Greater Seattle initially offered primary screening with guaiac-
based FOBT for individuals at average risk of colorectal cancer and follow-up colonoscopy 
for those with positive FOBTs; individuals at an increased risk of colorectal cancer because 
of family history were offered colonoscopy for primary screening. Later in the program, 
these sites allowed individuals at average risk to undergo colonoscopy for primary 
screening. In Baltimore City and Suffolk County, NY, the primary screening test was 
colonoscopy for all clients, regardless of whether they were of average or increased risk. At 
all 5 sites, individuals with a personal history of colorectal cancer or adenomas underwent 
colonoscopy for surveillance.
For each client screened in the CRCSDP, a standardized set of colorectal cancer clinical data 
elements (CCDEs) was collected and provided to the CDC. The CCDEs included 
information regarding a client’s age, personal history of colorectal polyps or cancer, and 
history of screening, which could be either self-reported or taken from the client’s medical 
record. The CCDEs also included information concerning whether the client was considered 
to be at an increased risk because of a family history of colorectal cancer; each site was 
allowed to define its own criteria for increased risk. For each screening and diagnostic test 
provided as part of the CRCSDP, test date, test indication, results, and recommendations for 
the next test were collected. The data described herein are from the CCDEs provided to the 
CDC at the end of the CRCSDP. Our analysis included an examination of the first screening 
test obtained by each client for which a result was reported. The data we report on 
colonoscopy include procedures performed either as the primary screening test; as follow-up 
to positive FOBTs; or for surveillance after a diagnosis of cancer or adenoma, except where 
indicated.
For each colonoscopy, the CCDEs included information regarding whether the cecum was 
reached, whether the bowel preparation was considered adequate by the clinician performing 
the procedure, and the clinician’s recommendation for which test the client should have next 
and when.
For each polyp or lesion identified, information was collected concerning the size, location, 
method and completeness of removal, and histology. This information was obtained by staff 
at each site from the endoscopy and pathology reports. Because endoscopy reporting was 
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not standardized for the CRCSDP, site staff occasionally needed to convert the terms found 
in reports (eg, to describe bowel preparation quality) to fit the categories specified in the 
CCDEs.
We considered clients to be at average risk of colorectal cancer if they did not report any 
personal history of colorectal cancer or adenomas and were not considered by staff at the 
site to be at an increased risk because of family history. We categorized each colonoscopy as 
complete or incomplete; incomplete colonoscopies were defined as those for which the 
cecum was not reached, bowel preparation was inadequate, and/or identified polyps or 
lesions were not completely removed.
We computed the cecal intubation rate as the percentage of colonoscopies in which the 
cecum was reached. We computed the adenoma detection rate as the percentage of 
colonoscopies in which at least 1 adenoma was reported; we excluded clients who reported 
having undergone colonoscopy before receiving services from the CRCSDP because 
adenomas are less prevalent among people who have undergone a previous colonoscopy.11 
Because adenoma prevalence varies by sex and age, we computed sex-specific adenoma 
detection rates for clients aged ≥ 50 years to allow comparison with published rates. We 
limited our assessment of clinician recommendation for the next test to those clients at 
average risk because individuals at increased risk may require testing at shorter intervals. 
For our analysis of recommendations for rescreening or surveillance intervals, we did not 
include data from Baltimore City (n = 462 clients) because its policy on data entry for this 
variable limited the recommended interval to program guidelines; recommendations that 
deviated from these guidelines were recorded elsewhere and not included in the CCDEs.
RESULTS
Fecal Occult Blood Test
Overall, 53% of the FOBTs that were distributed to clients were completed and returned. 
Percentages ranged from 47% of clients in Nebraska (1319 of 2813 clients) to 63% of clients 
in Greater Seattle (909 of 1447 clients) and 63% of clients in St. Louis (67 of 107 clients). 
Of all the clients who underwent FOBT, 1.9% were considered to be at an increased risk of 
colorectal cancer. St. Louis is not included in further FOBT analyses because the number of 
FOBTs collected was small.
Both Nebraska and Greater Seattle used high-sensitivity guaiac tests, such as the Hemoccult 
SENSA test (Beckman Coulter, Brea, Calif). In Nebraska, slides were developed in a central 
laboratory; in Greater Seattle, they were developed in community clinics. Of the 1319 
clients in Nebraska who had at least 1 FOBT, 75 (5.7%) had a positive result on the first 
test; 73 (97%) of these clients received a follow-up colonoscopy in the CRCSDP. Of the 909 
clients in Greater Seattle who underwent FOBT, 154 (17%) had a positive first test, 118 of 
whom (77%) received a follow-up colonoscopy. For 19 of the clients who did not receive a 
follow-up colonoscopy (50%) in the CRCSDP, the reason was patient refusal.
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Approximately one-fifth of clients with a positive FOBT in either Nebraska or Greater 
Seattle underwent a colonoscopy within 60 days of the positive FOBT; approximately two-
thirds underwent a colonoscopy within 120 days (Fig. 1).
Colonoscopy
A total of 3215 individuals underwent colonoscopy in the CRCSDP, either as a primary 
screening test (n = 2935), to follow up a positive FOBT (n = 210), or for surveillance in 
those clients with a personal history of colorectal cancer or adenomas (n = 70). Several 
indicators of quality are presented in Table 1 for initial colonoscopies received in the 
CRCSDP.
Cecal intubation rates ranged from 89.7% in St. Louis to 97.8% in Nebraska. At 4 of the 5 
sites, the data indicated that the quality of bowel preparation was adequate for at least 90% 
of examinations. In St. Louis, 65.5% of examinations were reported as having adequate 
bowel preparation, 17.1% as inadequate, and 17.4% did not have information regarding 
bowel preparation quality. The completeness of polyp removal was not reported for 11.5% 
of colonoscopies in St. Louis and 11.6% in Greater Seattle. Overall, 10.5% of colonoscopies 
were considered incomplete either because the cecum was not reached, bowel preparation 
was inadequate, and/or all polyps or lesions were not completely removed. Percentages 
ranged from 4.5% in Nebraska to 22.3% in St. Louis (data not shown).
Adenoma detection rates were computed for first-ever colonoscopies performed either as a 
primary screening test or as a diagnostic test after a positive FOBT for clients aged ≥ 50 
years (Table 2). Adenoma detection rates were higher overall for men (32.2%) than for 
women (21.1%), and ranged from 24.2% in Baltimore City to 41.5% in Greater Seattle for 
men and from 16.6% in Baltimore City to 26.8% in Greater Seattle for women. When 
colonoscopies in which the cecum was not reached and/or the bowel preparation was not 
adequate were excluded, adenoma detection rates changed only slightly (data not shown). 
Adenoma detection rates were higher for clients at an increased risk because of personal or 
family history (39.3% for men and 25.6% for women) compared with those at average risk 
(31.1% for men and 19.6% for women). The numbers of clients at an increased risk at each 
site were too small, especially for women, to allow for the calculation of meaningful site-
specific adenoma detection rates. The adenoma detection rate for clients in Nebraska (n = 
69) and Greater Seattle (n = 107) who underwent a colonoscopy to follow up a positive 
FOBT was approximately 20%.
Rescreening and Surveillance Recommendations After Colonoscopy
A total of 1606 clients at average risk underwent complete first colonoscopies in the 
CRCSDP in St. Louis; Nebraska; Suffolk County, NY; or Greater Seattle, either as their 
primary screening test or to follow up positive FOBTs. Sixty-three (3.9%) clients were 
excluded because their data regarding screening outcome or recommended interval to the 
next test were not complete. Of the 1543 clients with complete data, 2 were diagnosed with 
cancer. The recommended interval to the next test for the other clients is shown in Table 3; 4 
clients who had serrated adenoma(s) as their most severe finding are not included in Table 3 
because to the best of our knowledge, surveillance recommendations for this finding were 
Nadel et al. Page 5













not specified in guidelines published at that time.19 For comparison, intervals recommended 
in national screening and surveillance guidelines are provided in Table 4.19
Of the clients in whom no polyps were found, 70% were told to return in 10 years and 26% 
were told to return in 5 years to < 10 years. For clients whose colonoscopies found only 
hyperplastic or other nonadenomatous polyps (eg, inflammatory, hamartomatous, etc), 35% 
were told to return in 10 years, 48% to return in 5 years to < 10 years, and 17% to return in 
≤3 years. Among those clients with the most severe finding of 1 to 2 tubular adenomas 
measuring < 1 cm, 67% were told to return in 5 years and 30% were told to return in ≤ 3 
years. Of clients with at least 1 adenoma measuring ≥ 1 cm or with villous features or high-
grade dysplasia or at least 3 tubular adenomas of any size, 64% were told to return in 3 years 
and another 26% were told to return sooner.
Overall, 65% of the recommendations we analyzed adhered to published national guidelines, 
with the level of agreement varying by site. For clients in whom no polyps were found, 61% 
in Nebraska were told to return in 10 years, whereas 71% to 75% received this 
recommendation in St. Louis; Suffolk County, NY; and Greater Seattle (data not shown). 
The numbers of clients with other screening outcomes were too small at most sites to allow 
for meaningful comparisons.
DISCUSSION
To maximize the benefit of screening, programs should try not only to increase the number 
of eligible individuals who are screened, but they also should monitor the quality of 
screening and ensure that recommended clinical standards are being met. In this study, we 
examined indicators of the quality of screening provided at the 5 sites participating in the 
CDC-funded CRCSDP from 2005 to 2009. For colonoscopy, cecal intubation rates and 
adenoma detection rates (which are considered to be important quality indicators), reached 
target levels suggested by expert groups.11,20 However, recommended rescreening or 
surveillance intervals after colonoscopy were not in agreement with national guidelines for 
more than one-third of clients.19 Our study also identified a need to improve the 
documentation of important elements in the colonoscopy report.21
FOBT is a noninvasive, low-risk option for screening, and has been demonstrated to reduce 
deaths in randomized controlled trials.1–4 However, for this test to be effective, the 
following objectives must be met: patients must return their test kits, be rescreened on a 
regular basis, and receive follow-up colonoscopy if they have positive FOBTs. Meeting 
these requirements proved to be a formidable challenge for the CRCSDP. Although the 
CRCSDP was an organized program with established policies and oversight, return rates 
indicated substantial room for improvement, as did follow-up of positive tests at 1 site. 
Rescreening rates are addressed in another article in this supplement.18
Both Greater Seattle and Nebraska used the higher sensitivity version of the original guaiac-
based test, such as Hemoccult SENSA. The high-sensitivity test is recommended over the 
original test in current screening guidelines.5,6 The positivity rate was surprisingly high in 
Greater Seattle and may be associated with a failure to identify and exclude symptomatic 
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patients (eg, those with rectal bleeding or hemorrhoids) or the failure of clients to restrict 
their diet for testing. Dietary restriction is more important for the high-sensitivity test than 
for standard guaiac-based tests, but is not necessary for the fecal immunochemical tests 
because they are specific for human globin.6 In Greater Seattle, tests were developed and 
interpreted in the local clinics rather than at a laboratory. Quality control policies should be 
in place that ensure a standard process for developing and interpreting guaiac slides.
During the past decade, the use of colonoscopy, especially for screening, has increased 
dramatically.22,23 At the same time, concerns over the quality of performance of this 
procedure and variations in performance among endoscopists have intensified. In an effort to 
improve quality, recommendations for indicators that should be measured as part of ongoing 
quality improvement, along with target levels for selected indicators, have been developed 
and are published elsewhere.11,12,20,21 For an endoscopist to effectively examine the entire 
mucosal surface of the colon, the bowel must be adequately cleaned and the cecum must be 
reached. Therefore, adequate bowel preparation and cecal intubation are key quality 
indicators. When either is not achieved, or when polyps are not removed completely, the 
colonoscopy must be repeated at a shorter interval, thereby increasing cost, burden, and risk 
to the patient. Cecal intubation, adequacy of bowel preparation, completeness of polyp 
removal, and polyp descriptors such as size are critical to determining the appropriate 
surveillance interval.19 Therefore, explicit documentation of these elements by the 
endoscopist in the colonoscopy report is considered an important indicator of colonoscopy 
that meets high-quality standards.20,21 We found incomplete documentation of bowel 
preparation quality and of completeness of polyp removal at some CRCSDP sites. 
Deficiencies in the documentation of important elements also have been found in other 
settings, including those with electronic reporting systems.13,14
One key reporting element, the quality of bowel preparation, can be particularly 
problematic. This measure is subjective and endoscopists commonly use terms such as 
“excellent,” “good,” “fair,” and “poor” to describe it. In clinical practice, these terms do not 
have standardized definitions.12 The US Multi-Society Task Force on Colorectal Cancer 
(USMSTF) and the Quality Assurance Task Group of the National Colorectal Cancer 
Roundtable have recommended that bowel preparation be rated as “adequate” or 
“inadequate” to detect lesions measuring > 5 mm.11,21 In the CRCSDP, endoscopists used 
their usual report formats and terminology and site staff often had to classify bowel 
preparation quality as adequate or inadequate on the basis of the descriptors used by the 
endoscopists. Different site staff may have interpreted the terms differently when 
categorizing this data element, accounting for some of the differences in the percentage of 
examinations that were reported to be of adequate quality. It has been recommended that if 
bowel preparation is found to be inadequate in > 10% of examinations in a particular clinical 
practice, then preparation protocols and patient instructions should be assessed, and remedial 
steps should be taken to improve preparation quality.21
Cecal intubation was achieved in at least 94% of examinations at 4 of the 5 sites; at the 5th 
site, the rate was 90%. Although relatively low rates of cecal intubation have been reported 
in some studies,24–26 rates > 90% are commonly achieved, and many studies of screening 
colonoscopies have reported rates of ≥ 97%.11 The USMSTF has suggested quality 
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improvement targets of ≥ 90% for all examinations and ≥ 95% for screening examinations 
for cecal intubation rates that are adjusted by excluding procedures aborted because of 
inadequate bowel preparation or severe colitis.
Probably the most important quality indicator for colonoscopy is the actual prevalence of 
adenomas detected. Most studies comparing the performance of multiple endoscopists have 
identified significant disparities in the rate at which polyps or adenomas are identified.11,12 
The importance of the adenoma detection rate as a quality indicator was clearly 
demonstrated in a recent analysis of data from a population-based colonoscopy screening 
program in Poland, in which adenoma detection rates were found to be inversely related to 
the risk of interval colorectal cancer after screening colonoscopy.27 The adenoma detection 
rate is a function of the quality of bowel preparation, the examination technique, and the 
demographics of the patient population. The USMSTF has recommended that adenoma 
detection rates for people aged ≥ 50 years who receive first-time screening examinations 
should be ≥ 25% for men and ≥ 15% for women. In the United Kingdom, the National 
Health Service Bowel Cancer Screening Programme recently set its standard for the 
adenoma detection rate at ≥ 35%.28 Adenoma detection rates for the CRCSDP met the 
targets set by the USMSTF at all sites and, overall, were higher for clients at increased risk. 
A limitation of our assessment by risk level was that screening history, personal history of 
adenomas, and family history were self-reported by clients and therefore may not be 
accurate.
In 2006, consensus guidelines for surveillance after polypectomy were jointly published by 
the USMSTF and the American Cancer Society in an attempt to optimize the use of 
colonoscopic resources by shifting resources from unnecessarily intensive surveillance of 
low-risk polyps to screening (Table 4).19 Of the clients at average risk who underwent a 
complete colonoscopy in the CRCSDP either as a primary screening test or as a follow-up 
test to a positive FOBT, 35% were told to return sooner than recommended by national 
guidelines. For colonoscopies that found only hyperplastic polyps, some of the apparent 
disagreement with the 2006 national guidelines might be explained by growing concern that 
large or multiple hyperplastic polyps may require earlier follow-up. Updated guidelines 
published since the CRCSDP for the first time provide recommendations for surveillance of 
serrated polyps.29 A limitation in our analysis of rescreening and surveillance 
recommendations was that we do not know if there were other non-neoplasia-related 
findings that may have influenced the clinician. We also did not have access to the detailed 
findings for each site. There were situations, for example, that did not fall neatly into any of 
the outcome categories specified in the CCDEs and therefore site staff had to make 
subjective decisions.
Deviations from recommended surveillance intervals have been documented in clinical 
practice. When surveyed, many clinicians indicate that they choose shorter surveillance 
intervals than recommended in clinical practice guidelines.15 Surveillance that occurs too 
frequently provides little or no benefit while exposing patients to the risk of complications, 
increasing costs (measured both in financial and human terms), and wasting resources that 
could be better used for primary screening.30 Analysis of the actual use of surveillance 
colonoscopy by clinicians in 9 areas across the United States that are participating in the 
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Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial showed both significant 
overuse of colonoscopy among participants without adenomas or those with low-risk 
adenomas and substantial underuse among participants with advanced adenomas.16
We were not able to assess quality indicators by endoscopist or clinical practice. Ideally, 
quality indicators should be measured at the level of the endoscopist or, at least, the practice 
because problematic performance by individual clinicians can easily be masked when data 
from large numbers of clinicians are combined. We encourage sites to monitor quality 
indicators by endoscopist whenever possible. In an accompanying article in this supplement, 
quality indicators are assessed at the endoscopist level at 1 of the CRCSDP sites.31
Because the CRCSDP was an organized program with established policies and oversight, we 
would expect compliance with rescreening and surveillance recommendations, as well as 
with including recommended elements in the endoscopy report, to be lower in general 
clinical practice.
In the CDC’s current Colorectal Cancer Control Program, the CDC and site staff monitor 
quality indicators on a regular basis. We encourage screening programs to raise awareness 
among their clinical communities about the need for the routine monitoring of quality 
indicators as part of an ongoing quality improvement system.
Acknowledgments
We gratefully acknowledge William Helsel, William Kammerer, William Howe, and Tanner Rockwell of 
Information Management Services Inc for providing analytical and data management support.
FUNDING SUPPORT
The Colorectal Cancer Screening Demonstration Program evaluated in this supplement was funded by the Centers 
for Disease Control and Prevention Funding Opportunity Number RFA AA030.
REFERENCES
1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for 
fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328:1365–1371. 
[PubMed: 8474513] 
2. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence 
of colorectal cancer. N Engl J Med. 2000; 343:1603–1607. [PubMed: 11096167] 
3. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-
blood screening for colorectal cancer. Lancet. 1996; 348:1472–1477. [PubMed: 8942775] 
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for 
colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348:1467–1471. [PubMed: 8942774] 
5. U.S Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task 
Force recommendations statement. Ann Intern Med. 2008; 149:627–637. [PubMed: 18838716] 
6. Levin B, Lieberman DA, McFarland B, et al. American Cancer Society Colorectal Cancer Advisory 
Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. 
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 
2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008; 58:130–160. 
[PubMed: 18322143] 
Nadel et al. Page 9













7. Klabunde CN, Lanier D, Nadel MR, McLeod C, Yuan G, Vernon SW. Colorectal cancer screening 
by primary care physicians: recommendations and practices, 2006–2007. Am J Prev Med. 2009; 
37:8–16. [PubMed: 19442479] 
8. Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians’ methods 
for screening for fecal occult blood. Ann Intern Med. 2005; 142:86–94. [PubMed: 15657156] 
9. Nadel MR, Berkowitz Z, Klabunde CN, Smith RA, Coughlin SS, White MC. Fecal occult blood 
testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-
based recommendations. J Gen Intern Med. 2010; 25:833–839. [PubMed: 20383599] 
10. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Veterans Affairs Cooperative Study #380 
Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital 
rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005; 
142:81–85. [PubMed: 15657155] 
11. Rex DK, Bond JH, Winawer S, et al. U.S. Multi-Society Task Force on Colorectal Cancer. Quality 
in the technical performance of colonoscopy and the continuous quality improvement process for 
colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J 
Gastroenterol. 2002; 97:1296–1308. [PubMed: 12094842] 
12. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 
2006; 63(suppl 4):S16–S28. [PubMed: 16564908] 
13. Lieberman DA, Faigel DO, Logan JR, et al. Assessment of the quality of colonoscopy reports: 
results from a multicenter consortium. Gastrointest Endosc. 2009; 69(3 pt 2):645–653. [PubMed: 
19251005] 
14. Li J, Nadel MR, Poppell CF, Dwyer DM, Lieberman DA, Steinberger EK. Quality assessment of 
colonoscopy reporting: results from a statewide cancer screening program. Diagn Ther Endosc. 
2010; 2010 [published online ahead of print September 28, 2010]. pii: 419796. 
15. Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much 
colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med. 
2004; 141:264–271. [PubMed: 15313742] 
16. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community 
practice. Gastroenterology. 2010; 138:73–81. [PubMed: 19818779] 
17. Seeff LC, DeGroff A, Tangka F, et al. Development of a federally funded demonstration colorectal 
cancer screening program. Prev Chronic Dis. 2008; 5:A64. [PubMed: 18341799] 
18. Seeff LC, Royalty J, Helsel WE, et al. Clinical outcomes from the CDC’s Colorectal Cancer 
Screening Demonstration Program. Cancer. 2013; 119(suppl 15):2820–2833. [PubMed: 
23868476] 
19. Winawer S, Zauber AG, Fletcher RH, et al. US Multi-Society Task Force on Colorectal Cancer; 
American Cancer Society. Guidelines for colonoscopy surveillance after polypectomy: a 
consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American 
Cancer Society. Gastroenterology. 2006; 130:1872–1885. [PubMed: 16697750] 
20. Fletcher RH, Nadel MR, Allen JI, et al. The quality of colonoscopy services-responsibilities of 
referring clinicians: a consensus statement of the Quality Assurance Task Group, National 
Colorectal Cancer Roundtable. J Gen Intern Med. 2010; 25:1230–1234. [PubMed: 20703953] 
21. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: 
report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. 
Gastrointest Endosc. 2007; 65:757–766. [PubMed: 17466195] 
22. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer 
test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 
2008; 17:1623–1630. [PubMed: 18628413] 
23. Phillips KA, Liang SY, Ladabaum U, et al. Trends in colonoscopy for colorectal cancer screening. 
Med Care. 2007; 45:160–167. [PubMed: 17224779] 
24. Cotton PB, Connor P, McGee D, et al. Colonoscopy: practice variation among 69 hospital-based 
endoscopists. Gastrointest Endosc. 2003; 57:352–357. [PubMed: 12612515] 
25. Bowles CJ, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of 
colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer 
screening tomorrow? Gut. 2004; 53:277–283. [PubMed: 14724164] 
Nadel et al. Page 10













26. Shah HA, Paszat LF, Saskin R, Stukel TA, Rabeneck L. Factors associated with incomplete 
colonoscopy: a population-based study. Gastroenterology. 2007; 132:2297–2303. [PubMed: 
17570204] 
27. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of 
interval cancer. N Engl J Med. 2010; 362:1795–1803. [PubMed: 20463339] 
28. National Health Service Bowel Cancer Screening Programme. Quality Assurance Guidelines for 
Colonoscopy. Sheffield, UK: National Health Service Cancer Screening Programmes; 2011. NHS 
BCSP Pub. No. 6
29. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for 
colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-
Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143:844–857. [PubMed: 
22763141] 
30. Levin TR. Dealing with uncertainty: surveillance colonoscopy after polypectomy. Am J 
Gastroenterol. 2007; 102:1745–1747. [PubMed: 17686069] 
31. Lane DS, Messina CR, Cavanagh MF, Anderson JC. Delivering colonoscopy screening for low-
income populations in Suffolk County: strategies, outcomes, and benchmarks. Cancer. 2013; 
119(suppl 15):2842–2848. [PubMed: 23868478] 
Nadel et al. Page 11














The follow-up of positive fecal occult blood tests (FOBTs) with colonoscopy is shown for 
the areas of Nebraska and Greater Seattle in the Centers for Disease Control and 
Prevention’s Colorectal Cancer Screening Demonstration Program, 2005 through 2009.
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TABLE 4





Normal or hyperplastic polyp(s)b 10
1–2 tubular adenomas measuring <1 cm with no high-grade dysplasia and no villous histology 5–10
3–10 adenomas, or at least 1 adenoma measuring ≥1 cm or at least 1 adenoma with high-grade dysplasia or villous 
histology
3
>10 adenomas of any size or histology <3c
a
Adapted from Winawer S, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update of the 
US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130:1872–1885.19 These 
recommendations assume that the baseline colonoscopy reached the cecum, bowel preparation was adequate, and all polyps identified were 
completely removed.
b
Since the article by Winawer et al was published,19 evidence has been growing that large or multiple hyperplastic polyps in the proximal colon 
may require earlier follow-up.
c
Consider the possibility of a familial syndrome.
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